Navigation Links
Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain
Date:11/28/2008

INDIANAPOLIS, Nov. 28 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) has withdrawn its supplemental New Drug Application (sNDA) from the U.S. Food and Drug Administration (FDA) for Cymbalta(R) (duloxetine HCl) for the management of chronic pain. Lilly plans to resubmit the application in the first half of 2009, adding data from a recently completed positive study in chronic osteoarthritis pain of the knee.

The decision does not affect duloxetine's FDA-approved indications for major depressive disorder, generalized anxiety disorder, management of diabetic peripheral neuropathic pain and management of fibromyalgia.

Lilly submitted the chronic pain application in the second quarter of 2008 based primarily on outcomes of three clinical trials: one positive study in chronic osteoarthritis pain of the knee(i) and two studies(ii,iii), -- one positive and one that is supportive but didn't meet its primary endpoint -- in chronic low back pain. In discussions between Lilly and the FDA, agency reviewers raised questions about efficacy and dosing that revolved primarily around statistical methodology and study design.

"This was a difficult decision, but we believe the updated data package will give the FDA a broader basis for reviewing our application," said John Hayes, M.D., a Lilly Research Laboratories vice president at Lilly.

Chronic pain affects more than 50 million Americans(iv) and pain is a major cause of work absenteeism, underemployment and unemployment.(v,vi,vii,viii)

About Duloxetine

Serotonin and norepinephrine in the brain and spinal cord are believed to both mediate core mood symptoms and help regulate the perception of pain. Based on preclinical studies, Duloxetine is a balanced and potent reuptake inhibitor of serotonin and norepinephrine that is bel
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Daiichi Sankyo and Lilly Respond to Speculation on Status of Prasugrel New Drug Application
2. Lilly and Deciphera Pharmaceuticals Announce Licensing and Collaboration Agreement
3. Lilly Announces Initiation of Second Global Phase III Trial of Investigational Alzheimers Disease Compound
4. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
5. Phase II Data on Lillys Antibody Show It Affects Amyloid Beta, a Protein Believed To Be Associated with Alzheimers Disease
6. FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel
7. Lilly and TransPharma Medical Announce Licensing and Development Agreement
8. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
9. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
10. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
11. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... DUBLIN , January 15, 2014 Shire plc ... waived the Office of Fair Trading (OFT) approval condition to the ... Incorporated (NASDAQ: VPHM).   As a result of the ... Shire expects to complete the tender offer on January 24, 2014 ...
(Date:1/15/2014)... NEW YORK , January 15, 2014 ... BreedIT Ltd., the exclusive worldwide distributor of highly sophisticated ... that on January 7, 2014, the Company,s board of ... Ben-Zion Weiner as its new member of the ...
(Date:1/15/2014)... PALM BEACH GARDENS, Fla. , Jan. 15, 2014  In an ... C. difficile and TB in ambulances and other transport vehicles, an ... being used by rescue personnel for the first time. ... coming in contact with these deadly pathogens, West Palm ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Superbugs No Longer Ride In Rescue Vehicles 2
... , , SAN DIEGO, Aug. 27 ... Company has begun a clinical trial intended to secure U.S. regulatory approval ... determine the need for a repeat prostate biopsy. , ... studies and our European commercial experience, we believe that our PROGENSA PCA3 ...
... , , , ... an 82-year old New Orleans resident with severe aortic stenosis successfully had ... as angioplasty, a far cry from the traditional open heart procedure. Patients ... now have a potential new research option available regionally only through The ...
Cached Medicine Technology:Gen-Probe Begins U.S. Clinical Study of PROGENSA(R) PCA3 Assay, New Molecular Test to Help Assess Prostate Cancer Risk 2Gen-Probe Begins U.S. Clinical Study of PROGENSA(R) PCA3 Assay, New Molecular Test to Help Assess Prostate Cancer Risk 3Gen-Probe Begins U.S. Clinical Study of PROGENSA(R) PCA3 Assay, New Molecular Test to Help Assess Prostate Cancer Risk 4Ochsner Replaces Heart Valve Without Open Heart Surgery 2
(Date:7/11/2014)... Presently, disposable medical suppliers call for the ... segment. During the past two decades, the world market ... average 12.5% per year), primarily owing to the importance ... is the largest market for disposable medical supplies in ... second position is held by Europe with a 29% ...
(Date:7/11/2014)... July 11, 2014 The Corn ... years to 2014 on the heels of fresh biofuel ... farmers to dedicate a larger share of their farmland ... specifically, the regulations required the mixing of 5.0% renewable ... production in the United States created a key export ...
(Date:7/11/2014)... Ticket Down is a reliable source ... Amphitheatre in Wheatland, CA. In the Sacramento California ... the Sleep Train Amphitheatre can do for music fans. The ... the course of its existence and can seat 18,500 fans ... Wheatland (Sacramento metro area) will host the “That’s My Kind ...
(Date:7/11/2014)... Pigments are insoluble colorants, which usually consist of ... coating, opacity, and coloring. These are water and oil ... substances such as paper, paints, plastics, and concrete. Binders ... impart color to the substance. Some examples of pigments ... , The coloring action of pigments is due to ...
(Date:7/11/2014)... York, NY (PRWEB) July 11, 2014 ... dramatic increase in men seeking cosmetic surgery and hair ... year. With such an expansive range of medical tourism ... exceptional plastic surgery costs and achieve the ... to be renowned as the top name in the ...
Breaking Medicine News(10 mins):Health News:Global Disposable Medical Supplies Market to See Robust Growth Through Next Decade, According to New TriMark Report Available at MarketPublishers.com 2Health News:Global Disposable Medical Supplies Market to See Robust Growth Through Next Decade, According to New TriMark Report Available at MarketPublishers.com 3Health News:Corn Farming in Canada Industry Market Research Report Now Available From IBISWorld 2Health News:Corn Farming in Canada Industry Market Research Report Now Available From IBISWorld 3Health News:Luke Bryan Tickets Sleep Train Amphitheatre in Wheatland, CA (Sacramento): Ticket Down has Slashed Ticket Prices on Luke Bryan in Wheatland at Sleep Train 2Health News:Luke Bryan Tickets Sleep Train Amphitheatre in Wheatland, CA (Sacramento): Ticket Down has Slashed Ticket Prices on Luke Bryan in Wheatland at Sleep Train 3Health News:Americas Pigments Market Worth 1,099 Thousand MT by 2018 - New Report by MicroMarket Monitor 2Health News:Americas Pigments Market Worth 1,099 Thousand MT by 2018 - New Report by MicroMarket Monitor 3Health News:VisitandCare.com Reports Increase in Cosmetic and Hair Transplant Procedures for Men 2Health News:VisitandCare.com Reports Increase in Cosmetic and Hair Transplant Procedures for Men 3
... a 47-year-old man who had worked for a Hindustan Lever ... who had also been exposed to toxic mercury, to the ... than 500 protestors, who said he had been slowly poisoned ... an autopsy to assess the possibility of mercury-induced damage. ...
... new study examined the connection between Baltimore City’s needle ... ,Individuals who enter treatment programs for drug addiction were ... Baltimore City needle exchange programs. ,The ... of Public Health highlights the need for treatment facilities ...
... always the result of a subtle marriage between a ... an appropriate excipient// (a neutral substance in which the ... absorbed by the body). Thus the necessary tablet, capsule ... biodegradable materials were used instead of these neutral excipients? ...
... multiple positive social outcomes,// research conducted in rural ... of the Journal of Acquired Immune Deficiency Syndromes ... appear to lead to stigmatisation or an increase ... increase in the incidence of domestic violence against ...
... transition service has been instituted by the NHS trust to ... ,‘Minding the Gap’, a document enabled by ... regular service for 16- to 18-year-olds, in Durham and Darlington. ... out to the teenagers suffering health problems across six primary ...
... Complementary //and Alternative Medicine (NCCAM) at the National Institutes ... better, especially about alternative therapies they are trying out ... ,This is the outcome of a survey conducted ... 1600 patients, and their doctors. ,It ...
Cached Medicine News:Health News:Ex-workers Ask HLL to Accept Liability for Mercury Deaths 2Health News:Drug Treatment Seekers Likely to Use Needle Exchange 2Health News:New Generation - Medicinal Products 2Health News:New Generation - Medicinal Products 3Health News:HIV Home-based Care Produces Positive Outcomes in Uganda 2Health News:HIV Home-based Care Produces Positive Outcomes in Uganda 3Health News:Elderly Patients Usually Keep Mum About Use of Alternative Medicine , Reveals Survey 2
Easy-to-use system for displaced femoral neck fractures in the low demand patient....
The APR Hip System offers a complete line of stems to precisely match patients' anatomic needs and address surgeon preferences....
Dual offset femoral stems, hip stems that provide unique and competitive features....
The P.S.L. stem is manufactured from cobalt chrome and is available with or without porous coating to give the surgeon the option of utilizing either the cementless of cemented technique at his or he...
Medicine Products: